Home Tags PRO1184

Tag: PRO1184

FDA Grants Fast Track Designation to Rinatabart Sesutecan for Patients with...

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rinatabart sesutecan (Rina-S; PRO1184), a folate receptor alpha (FRα / FOLR1)...

First Patient Dosed with PRO1184 and PRO1160 Cleared for Study Initiation...

Dosing has initiated in the Phase 1 first-in-human clinical trial of PRO1184 (NCT05579366),  an antibody-drug conjugates or ADC being developed by ProfoundBio comprising a folate receptor alpha-directed antibody conjugated to the exatecan payload using a novel, proprietary hydrophilic linker.

ProfoundBio Completes US $70 Million Series A+ Financing, Advancing Antibody-Drug Conjugate...

China's ProfoundBio, a biotech company based in the Seattle area, WA, USA and Suzhou, China, focuses on the development of novel targeted therapies.  Earlier this week the...

X